[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperinflation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperinflation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100598627","phase-4-a-study-to-investigate-the-effect-of-budesonideglycopyrroniumformoterol-fumarate-metered-dose-inhaler-bgf-mdi-compared-with-placebo-mdi-on-heart-and-lung-function-in-participants-with-chronic-obstructive-pulmonary-disease-copd-and-hyperinflation-100598627",false,"NCT07073950","A Study to Investigate the Effect of Budesonide\u002FGlycopyrronium\u002FFormoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide\u002FGlycopyrronium\u002FFormoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation","ORATOS","Key Inclusion Criteria:\n\n* Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking.\n* A diagnosis of COPD confirmed by a post-bronchodilator forced expiratory volume in 1 second\u002Fforced vital capacity (FEV1\u002FFVC) \\\u003C 0.7.\n* At Visit 1: A pre-bronchodilator FEV1 \\\u003C 80%.\n* At Visit 1: Peripheral blood eosinophil count \\\u003C 300 cells\u002Fcubic millimeter (mm³), with no recorded history of eosinophil count \\> 300 cells\u002Fmm³ in the past 12 months.\n* At Visit 1: Modified Medical Research Council (mMRC) ≥ 1.\n* At Visit 2: A pre-bronchodilator functional residual capacity (FRC) of \\> 135% of predicted normal FRC.\n* At Visit 2: A post-bronchodilator FEV1 ≥ 30% and \\\u003C 80% of the predicted normal value.\n* Participants must be on mono-, dual-, or triple-inhaled maintenance COPD treatment.\n* Female participants must either be not of childbearing potential or using a form of highly effective birth control.\n* All women of child bearing potential must have a negative pregnancy test at the Visit 1.\n\nExclusion Criteria:\n\n* A current diagnosis of asthma, asthma-COPD overlap, or any other chronic respiratory disease other than COPD, such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.\n* History of a COPD exacerbation that required hospitalisation, or 2 or more COPD exacerbations that required systemic corticosteroids.\n* History of myocardial infarction or acute coronary syndrome.\n* History or current clinically significant atrial or ventricular arrhythmia to be confirmed by electrocardiogram (ECG).\n* Participants with a cardiac implantable electronic device, including pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy.\n* Participants with ECG QTcF interval at Visit 1 \\> 460 milliseconds (ms) for males and \\> 480 ms for females.\n* Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and\u002For during the screening\u002Frun-in period.\n* Participants with lung lobectomy, lung volume reduction (during the study and within 3 months of Visit 1), or lung transplantation.","ALL","40 Years","80 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.",[28,29],"Chronic Obstructive Pulmonary Disease","Hyperinflation",[31,32,33,34],"Metered Dose Inhalers (MDI)","Inhaled Corticosteroid (ICS)","Long-acting muscarinic antagonist (LAMA)","Long-acting beta2 agonist (LABA)","RECRUITING","2026-07-01",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2025-11-24",{"date":43,"type":22},"2027-05-31",{"name":45,"class":46},"AstraZeneca","INDUSTRY",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":74,"locationsCount":77},"100556006","effect-of-elastic-chest-compression-on-functional-exercise-capacity-and-respiratory-performance-in-patients-with-copd-100556006","NCT06519474","Effect of Elastic Chest Compression on Functional Exercise Capacity and Respiratory Performance in Patients With COPD","Inclusion Criteria:\n\n* at least 20 years old\n* has a clinical diagnosis of COPD without infection or acute exacerbation in the previous four weeks\n* is capable of cooperating with the required tests and measurements of the study\n\nExclusion Criteria:\n\n* has any clinical diagnosis that could affect test outcomes (e.g., neuromyopathy)\n* has experienced unstable angina or an acute myocardial infarction within the last month\n* has adjusted COPD related medication within the last month\n* a Mini-Mental State Examination (MMSE) score below 24","20 Years",{"count":56,"type":22},17,[58],"NA","The goal of this clinical trial is to investigate the effects of elastic chest compression on functional exercise capacity and respiratory performance of patients with COPD. The main questions it aims to answer are:\n\nIs there difference in functional exercise capacity and respiratory performance without or with the use of elastic upper chest compression? Is there difference in functional exercise capacity and respiratory performance between the use of elastic upper chest compression and elastic lower chest compression?\n\nParticipants will:\n\nBe evaluated under three conditions on three different days: without elastic compression, with upper chest compression, and with lower chest compression, with the order of compression application randomly assigned.\n\nThe functional capacity and respiratory muscle performance of all patients will be evaluated.\n\nThe days for evaluation will be at least three days apart from each other.",[61,29],"COPD",[63,64,65,66,67],"chronic obstructive pulmonary disease","dynamic hyperinflation","elastic chest compression","functional exercise capacity","respiratory performance","2024-07-19",{"date":70,"type":39},"2024-07-25",{"date":72,"type":39},"2024-07-10",{"date":43,"type":22},{"name":75,"class":76},"National Taiwan University Hospital","OTHER",1]